Pfizer Halts Ranbaxy's Diflucan Generic With Court Ruling

Law360, New York (March 12, 2004, 12:00 AM EST) -- The U.S. District Court in Washington, D.C. has upheld Pfizer’s six-month pediatric exclusivity for its top selling anti-fungal medicine, Diflucan.

The court’s decision keeps a generic version by Indian drugmaker Ranbaxy Laboratories Ltd. off the market until July 29.

The ruling came in response to a suit filed by the generic manufacturer Ranbaxy contending that its generic version of Diflucan was not subject to the exclusivity period for Pfizer's product.

A previous lawsuit brought by Pfizer against Ranbaxy for infringement of its patent for Diflucan was...
To view the full article, register now.